<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2000
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
Initial Depositor
(Exact name of registrant as specified in its charter)
Pharmaceutical HOLDRS(SM) Trust
(Issuer with respect to the receipts)
DELAWARE
(State or other jurisdiction of incorporation)
333-95805
333-92161
(Commission File Number)
13-5674085
(I.R.S. Employer Identification No.)
250 Vesey Street
New York, New York 10281
(Address of principal executive offices and zip code)
(212) 449-1000
(Registrant's telephone number, including area code)
Page 1 of 5 pages.
The Exhibit Index appears at Page 4.
<PAGE>
Item 5. Other Events
On June 19, 2000, Pfizer Inc. completed its acquisition of Warner-
Lambert Company, exchanging 2.75 shares of Pfizer common stock for each share of
Warner-Lambert common stock. As a result, the eight shares of Warner Lambert
previously represented in each round-lot of 100 Pharmaceutical HOLDRS have been
exchanged for 22 shares of Pfizer. The share amount of Pfizer represented by a
round-lot of 100 Pharmaceutical Holders is now 58.
On March 16, 2000, Biovail Corporation International changed its name
to Biovail Corporation.
On May 23, 2000 King Pharmaceuticals, Inc. began trading on the New
York Stock Exchange under the symbol "KG".
In March 2000, Monsanto Company merged with Pharmacia & Upjohn, Inc.,
creating the combined company Pharmacia Corporation. As a result, shares of
Pharmacia Corporation were distributed to holders of Pharmaceutical HOLDRS and
shares of common stock of Pharmacia & Upjohn are no longer represented in the
Pharmaceutical HOLDRS.
The share amounts set forth in Exhibit 99 below reflect all previous
stock splits. The stock prices in the tables set forth in Annex A of the base
prospectus will not be adjusted to account for the stock splits.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
(99) Pharmaceutical HOLDRS(SM) Trust Prospectus Supplement dated
June 30, 2000 to Prospectus dated January 31, 2000.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MERRILL LYNCH, PIERCE, FENNER &
SMITH INCORPORATED
Date: June 30, 2000 By: /s/ STEPHEN G. BODURTHA
-----------------------
Name: Stephen G. Bodurtha
Title: Attorney-in-Fact
3
<PAGE>
EXHIBIT INDEX
Number and Description of Exhibit Sequential
--------------------------------- Page Number
-----------
(99) Pharmaceutical HOLDRS(SM) Trust Prospectus Pg. 5
Supplement dated June 30, 2000 to
Prospectus dated January 31, 2000.
4
